Engineering Bacteria as Living Therapeutics in Cancer Therapy
Cancer is the second-leading cause of death globally, yet traditional therapies like chemotherapy face significant limitations. Recent advances in synthetic biology enable the design of various genetic circuits and the reprogramming of biological systems. Collectively, these efforts have led to the repurposing of engineered bacteria as therapeutics to achieve tumor targeting, tumor microenvironment modulation, and anticancer drug release. Here, these recent efforts are reviewed and discussed the challenges and future opportunities.
Authors
- W.-F. Yuan (ORCID: https://orcid.org/0000-0003-2296-0443)
- Jiangfeng Chen (ORCID: https://orcid.org/0000-0003-0147-1106)
- Zhuojun Dai (ORCID: https://orcid.org/0000-0002-3791-5808)
- Jiao Zhang (ORCID: https://orcid.org/0000-0003-0277-9145)
- Guoqing Wang (ORCID: https://orcid.org/0000-0001-9326-3755)
- Jiaqi Chen (ORCID: https://orcid.org/0000-0002-1582-3195)
- Yixuan Chen (ORCID: https://orcid.org/0000-0003-1856-6689)
Institutions
- Jilin University (CN)
- University of Macau (MO)
- Jilin Medical University (CN)
- Shenzhen Institutes of Advanced Technology (CN)
- University of Chinese Academy of Sciences (CN)
Publication Details
- Journal
- Advanced Science
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1002/advs.202507820
- Citations
- 2
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.47
Funders
- National Natural Science Foundation of China
- Chinese Academy of Sciences
- National Key Research and Development Program of China